Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyUpper Ohio Valley HIPEC Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentHealth Plan of the Upper Ohio Valley, Inc.Policy 21641356

    Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    Customize your policy alerts

    Sign up for healthplanofupperohiovalley Policy 21641356 alerts

    Get alerted when Policy 21641356 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of HIPEC, also called intraperitoneal hyperthermic chemotherapy, when performed with cytoreductive surgery for selected advanced abdominal and peritoneal malignancies. It applies to all lines of business and requires medical-necessity documentation and precertification support.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyHyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date12/1/2026
    Next Review Date12/1/2027
    Key ActionSubmit medical-record documentation supporting medical necessity with precertification.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    41–42°CBath temperature
    FIGO IIIEligible ovarian stage
    100 mg/m²Cisplatin regimen
    96547/96548HIPEC codes
    Experimental

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Other indications

    Coverage Criteria

    Initial ovarian, fallopian tube, or primary peritoneal cancer therapy

    Covered when all of the following indications are met:

    Initial ovarian, fallopian tube, or primary peritoneal cancer therapy: Newly diagnosed histologically confirmed epithelial ovarian cancer or fallopian tube/primary peritoneal carcinoma at the time of interval cytoreductive surgery; FIGO stage III disease; response or stable disease on neoadjuvant chemotherapy; anticipated complete or optimal cytoreduction; and adequate renal function and performance status for cisplatin.FIGO stage III; cisplatin 100 mg/m² intraperitoneally over 90 minutes

    The evidence-supported regimen is cisplatin 100 mg/m² intraperitoneally over 90 minutes.

    Other covered indications

    The following are also covered indications when complete or near-complete cytoreduction is anticipated:

    Covered peritoneal surface malignancy indications: Treatment of acellular mucin, low-grade mucinous carcinoma peritonei (DPAM), high-grade mucinous carcinoma peritonei, high-grade mucinous carcinoma peritonei with signet ring cells, peritoneal mesothelioma, goblet cell adenocarcinoma, pseudomyxoma peritonei, or resectable appendiceal disease.Complete or near-complete cytoreduction anticipated

    As appropriate, the service should be performed at an experienced peritoneal-surface malignancy center.

    HIPEC is non-covered and considered experimental and investigational for indications other than those expressly covered by this policy because available scientific evidence is insufficient or does not support coverage. Non-covered indications include bladder, cecal, colon, colorectal signet ring, desmoplastic small round cell, hepatocellular, intrapleural mesothelioma, mixed germ cell, pancreatic, small bowel adenocarcinoma, thymic, and uterine leiomyosarcoma cancers. HIPEC is also non-covered for peritoneal surface malignancy other than mucinous carcinoma peritonei or peritoneal mesothelioma. Gastric peritoneal metastasis is not covered outside the PERISCOPE II clinical trial.

    HIPEC performed at primary cytoreduction is non-covered. The policy also does not cover extrapolation of the OVHIPEC-1 indication to FIGO stage IV disease; these settings are outside the covered indication.

    HIPEC is not medically necessary when planned cytoreduction surgery is absent.

    Coding and Treatment Parameters

    Medicare NCD hyperthermia codes outside this HIPEC policyCPT
    77605Hyperthermia treatment for cancer
    77610Hyperthermia treatment for cancer
    77615Hyperthermia treatment for cancer
    77620Hyperthermia treatment for cancer
    HIPEC procedure codesCPTCovered
    96547Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)
    96548Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)
    Chemotherapy bath temperature
    TemperatureAbout 41 to 42°C
    Equivalent Fahrenheit range106 to 108°F
    ApplicationThe warmed liquid chemotherapy solution is pumped directly into the empty abdominal cavity
    Chemotherapy bath circulation time
    Circulation time60 to 90 minutes
    Treatment purposeThe warm bath circulates to destroy remaining microscopic cancer cells
    Treatment location

    Provider Actions and Coverage Alerts

    Prior Authorization

    Precertification Required

    Precertification is required for HIPEC. The medical record supporting medical necessity must be available with precertification.

    Documentation Required

    Required Precertification Documentation

    Submit documentation supporting the diagnosis, resectability, anticipated completeness of cytoreduction, and clinical appropriateness of HIPEC with the precertification request.

    • Pathology confirming the diagnosis
    • Imaging and/or operative assessment of resectability and anticipated completeness of cytoreduction
    • Multidisciplinary evaluation
    • Performance status, comorbidity, and organ-function assessment, including renal-function review for cisplatin-containing regimens
    • Institutional HIPEC protocol with perioperative safety and toxicity-management measures

    Background

    Hyperthermic intraperitoneal chemotherapy (HIPEC) is a two-step procedure. The surgeon first removes visible tumor and diseased tissue through cytoreductive surgery, then circulates a heated chemotherapy solution directly within the abdominal cavity to address residual microscopic disease. The chemotherapy bath is typically heated to approximately 41–42°C (106–108°F) and circulated for 60–90 minutes.

    Definitions

    Hyperthermic intraperitoneal chemotherapy (HIPEC)
    Procedure typeA two-step medical procedure
    First stepCytoreductive surgery removes visible tumors and diseased tissue from the abdominal lining and organs
    Second stepA heated chemotherapy wash is pumped and circulated directly into the empty abdominal cavity
    Treatment goalThe heated wash treats remaining microscopic cancer cells
    Intraperitoneal hyperthermic chemotherapy (IPHC)
    Alternative nameIntraperitoneal hyperthermic chemotherapy (IPHC) is another name for HIPEC
    Related procedure

    Line of Therapy

    First-line treatment placement criteria

    First-line coverage requires all of the following:

    Interval cytoreductive surgery after neoadjuvant chemotherapy: HIPEC for newly diagnosed histologically confirmed epithelial ovarian cancer or fallopian tube/primary peritoneal carcinoma is performed at interval cytoreductive surgery; the disease is FIGO stage III; the disease has responded or remained stable on neoadjuvant chemotherapy; complete or optimal cytoreduction is anticipated; and renal function and performance status are adequate for cisplatin.All FIGO stage III disease; cisplatin 100 mg/m² intraperitoneally over 90 minutes

    The evidence-supported regimen is cisplatin 100 mg/m² intraperitoneally over 90 minutes.

    Covered Regimens

    RegimenCovered indicationCoverage
    Cisplatin 100 mg/m² intraperitoneally over 90 minutes
    Newly diagnosed, histologically confirmed epithelial ovarian cancer or fallopian tube/primary peritoneal carcinoma at the time of interval cytoreductive surgery; FIGO stage III disease; response or stable disease on neoadjuvant chemotherapy; anticipated complete or optimal cytoreduction; and adequate renal function and performance status for cisplatin.
    Covered
    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyHyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date12/1/2026
    Next Review Date12/1/2027
    Key ActionSubmit medical-record documentation supporting medical necessity with precertification.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Treatment ParametersProvider Actions and Coverage AlertsBackgroundDefinitionsLine of TherapyCovered Regimens
    The chemotherapy solution circulates directly in the abdominal cavity
    Ovarian cancer HIPEC regimen
    DrugCisplatin
    Dose100 mg/m²
    RouteIntraperitoneal
    Administration timeOver 90 minutes
    Covered settingNewly diagnosed FIGO stage III epithelial ovarian cancer or fallopian tube/primary peritoneal carcinoma at interval cytoreductive surgery after response or stable disease on neoadjuvant chemotherapy
  1. Documented shared decision-making
  2. Denial Risk

    Unlisted or Excluded Cancer Indication

    HIPEC is experimental and investigational for unlisted or excluded cancer indications and is not covered unless the indication is expressly covered under this policy.

    • Examples of excluded indications include bladder, cecal, colon, colorectal signet ring, hepatocellular, pancreatic, small bowel adenocarcinoma, thymic, and uterine leiomyosarcoma cancers; intrapleural mesothelioma; mixed germ cell tumor; desmoplastic small round cell tumor; and other non-covered peritoneal surface malignancies.
    • The exclusion list is not all-inclusive.
    Denial Risk

    Recurrent Disease Not Covered

    HIPEC for recurrent disease is not covered. Current evidence is insufficient to support secondary cytoreduction or HIPEC in recurrence.

    Denial Risk

    Primary Cytoreduction or Stage IV Ovarian Disease

    HIPEC at primary cytoreduction, or extrapolation of the OVHIPEC-1 indication to FIGO stage IV ovarian disease, is not covered under this policy.

    Denial Risk

    Planned Cytoreduction Required

    HIPEC is not medically necessary when planned cytoreduction surgery is absent.

    Denial Risk

    Gastric Peritoneal Metastasis

    Gastric peritoneal metastasis is not covered outside the PERISCOPE II clinical trial.

    IPHC refers to the same two-step procedure combining cytoreductive surgery with a heated chemotherapy wash
    Treatment locationThe heated chemotherapy solution is circulated directly within the abdominal cavity